This edition presents key opinion leader (KOL) views on recent developments in the ulcerative colitis (UC) market. Topics covered include; Celgene reporting data from a Phase II trial of Otezla (apremilast) in patients...

Gain new key opinion leader (KOL) insights on the latest events happening in the CRC treatment landscape Topics covered include expert opinions on; the potential of MabVax Therapeutics’ human antibody-based...

This edition presents key opinion leader (KOL) views on recent developments in the renal cell carcinoma (RCC) market. Topics covered include; the success of Roche’s Phase III IMmotion151 trial of atezolizumab...

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in NASH market, including; Intercept Pharmaceuticals announcing...

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the FDA approval of Lynparza (olaparib; AstraZeneca)...

This edition presents key opinion leader (KOL) views on recent developments in the chronic lymphocytic leukaemia (CLL) market. Topics covered include: full results from the Phase III study of AbbVie/Roche’s...

This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market. Topics covered include: Bristol-Myers Squibb (BMS) presenting positive data from a Phase I/II study...

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the chronic obstructive pulmonary disease (COPD) market,...